MiniMed Group (MMED) Competitors

MiniMed Group logo
$16.18 -0.82 (-4.80%)
As of 03:31 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MMED vs. ZBH, GKOS, BAX, SNN, and PEN

Should you buy MiniMed Group stock or one of its competitors? MiniMed Group's main competitors and comparable companies include Zimmer Biomet (ZBH), Glaukos (GKOS), Baxter International (BAX), Smith & Nephew SNATS (SNN), and Penumbra (PEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does MiniMed Group compare to Zimmer Biomet?

MiniMed Group (NASDAQ:MMED) and Zimmer Biomet (NYSE:ZBH) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Zimmer Biomet has higher revenue and earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiniMed Group$3.22B1.48-$333M-$0.68N/A
Zimmer Biomet$8.23B2.38$705.20M$3.9526.18

88.9% of Zimmer Biomet shares are owned by institutional investors. 0.0% of MiniMed Group shares are owned by insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zimmer Biomet has a net margin of 8.95% compared to MiniMed Group's net margin of 0.00%. Zimmer Biomet's return on equity of 13.02% beat MiniMed Group's return on equity.

Company Net Margins Return on Equity Return on Assets
MiniMed GroupN/A N/A N/A
Zimmer Biomet 8.95%13.02%7.17%

MiniMed Group presently has a consensus price target of $24.13, indicating a potential upside of 42.00%. Zimmer Biomet has a consensus price target of $114.32, indicating a potential upside of 10.54%. Given MiniMed Group's stronger consensus rating and higher possible upside, equities analysts plainly believe MiniMed Group is more favorable than Zimmer Biomet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiniMed Group
1 Sell rating(s)
4 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.68
Zimmer Biomet
1 Sell rating(s)
15 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.29

In the previous week, Zimmer Biomet had 8 more articles in the media than MiniMed Group. MarketBeat recorded 16 mentions for Zimmer Biomet and 8 mentions for MiniMed Group. Zimmer Biomet's average media sentiment score of 0.50 beat MiniMed Group's score of 0.45 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiniMed Group
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zimmer Biomet
4 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Zimmer Biomet beats MiniMed Group on 12 of the 15 factors compared between the two stocks.

How does MiniMed Group compare to Glaukos?

Glaukos (NYSE:GKOS) and MiniMed Group (NASDAQ:MMED) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

In the previous week, Glaukos had 6 more articles in the media than MiniMed Group. MarketBeat recorded 14 mentions for Glaukos and 8 mentions for MiniMed Group. Glaukos' average media sentiment score of 0.94 beat MiniMed Group's score of 0.45 indicating that Glaukos is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Glaukos
6 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MiniMed Group
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Glaukos currently has a consensus target price of $218.00, indicating a potential downside of 6.27%. MiniMed Group has a consensus target price of $24.13, indicating a potential upside of 42.00%. Given MiniMed Group's higher probable upside, analysts plainly believe MiniMed Group is more favorable than Glaukos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Glaukos
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88
MiniMed Group
1 Sell rating(s)
4 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.68

MiniMed Group has a net margin of 0.00% compared to Glaukos' net margin of -24.60%. MiniMed Group's return on equity of 0.00% beat Glaukos' return on equity.

Company Net Margins Return on Equity Return on Assets
Glaukos-24.60% -0.97% -0.71%
MiniMed Group N/A N/A N/A

Glaukos has higher earnings, but lower revenue than MiniMed Group. Glaukos is trading at a lower price-to-earnings ratio than MiniMed Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Glaukos$507.44M27.13-$187.69M-$2.94N/A
MiniMed Group$3.10B1.54-$333M-$0.68N/A

99.0% of Glaukos shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Comparatively, 0.0% of MiniMed Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Glaukos beats MiniMed Group on 8 of the 15 factors compared between the two stocks.

How does MiniMed Group compare to Baxter International?

Baxter International (NYSE:BAX) and MiniMed Group (NASDAQ:MMED) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

In the previous week, MiniMed Group had 5 more articles in the media than Baxter International. MarketBeat recorded 8 mentions for MiniMed Group and 3 mentions for Baxter International. Baxter International's average media sentiment score of 0.75 beat MiniMed Group's score of 0.45 indicating that Baxter International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Baxter International
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MiniMed Group
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Baxter International presently has a consensus target price of $23.27, suggesting a potential downside of 11.03%. MiniMed Group has a consensus target price of $24.13, suggesting a potential upside of 42.00%. Given MiniMed Group's stronger consensus rating and higher probable upside, analysts clearly believe MiniMed Group is more favorable than Baxter International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baxter International
3 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86
MiniMed Group
1 Sell rating(s)
4 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.68

90.2% of Baxter International shares are owned by institutional investors. 0.2% of Baxter International shares are owned by insiders. Comparatively, 0.0% of MiniMed Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MiniMed Group has a net margin of 0.00% compared to Baxter International's net margin of -6.23%. Baxter International's return on equity of 16.23% beat MiniMed Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Baxter International-6.23% 16.23% 5.08%
MiniMed Group N/A N/A N/A

MiniMed Group has lower revenue, but higher earnings than Baxter International. MiniMed Group is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baxter International$11.24B1.20-$957M-$1.41N/A
MiniMed Group$3.10B1.54-$333M-$0.68N/A

Summary

MiniMed Group beats Baxter International on 8 of the 14 factors compared between the two stocks.

How does MiniMed Group compare to Smith & Nephew SNATS?

MiniMed Group (NASDAQ:MMED) and Smith & Nephew SNATS (NYSE:SNN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.0% of MiniMed Group shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Smith & Nephew SNATS has higher revenue and earnings than MiniMed Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiniMed Group$3.10B1.54-$333M-$0.68N/A
Smith & Nephew SNATS$6.30B2.02$625MN/AN/A

Company Net Margins Return on Equity Return on Assets
MiniMed GroupN/A N/A N/A
Smith & Nephew SNATS N/A N/A N/A

In the previous week, MiniMed Group had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 8 mentions for MiniMed Group and 5 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 0.45 beat MiniMed Group's score of 0.45 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiniMed Group
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Smith & Nephew SNATS
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MiniMed Group presently has a consensus price target of $24.13, suggesting a potential upside of 42.00%. Smith & Nephew SNATS has a consensus price target of $31.91, suggesting a potential upside of 5.19%. Given MiniMed Group's stronger consensus rating and higher possible upside, equities analysts plainly believe MiniMed Group is more favorable than Smith & Nephew SNATS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiniMed Group
1 Sell rating(s)
4 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.68
Smith & Nephew SNATS
2 Sell rating(s)
8 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.91

Summary

Smith & Nephew SNATS beats MiniMed Group on 6 of the 10 factors compared between the two stocks.

How does MiniMed Group compare to Penumbra?

MiniMed Group (NASDAQ:MMED) and Penumbra (NYSE:PEN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

88.9% of Penumbra shares are owned by institutional investors. 0.0% of MiniMed Group shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Penumbra has a net margin of 10.06% compared to MiniMed Group's net margin of 0.00%. Penumbra's return on equity of 10.39% beat MiniMed Group's return on equity.

Company Net Margins Return on Equity Return on Assets
MiniMed GroupN/A N/A N/A
Penumbra 10.06%10.39%8.09%

MiniMed Group currently has a consensus price target of $24.13, suggesting a potential upside of 42.00%. Penumbra has a consensus price target of $367.07, suggesting a potential upside of 14.57%. Given MiniMed Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe MiniMed Group is more favorable than Penumbra.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiniMed Group
1 Sell rating(s)
4 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.68
Penumbra
0 Sell rating(s)
14 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.18

In the previous week, MiniMed Group had 5 more articles in the media than Penumbra. MarketBeat recorded 8 mentions for MiniMed Group and 3 mentions for Penumbra. MiniMed Group's average media sentiment score of 0.45 beat Penumbra's score of 0.35 indicating that MiniMed Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiniMed Group
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Penumbra
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Penumbra has lower revenue, but higher earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiniMed Group$3.10B1.54-$333M-$0.68N/A
Penumbra$1.40B9.00$177.69M$3.9780.70

Summary

Penumbra beats MiniMed Group on 8 of the 14 factors compared between the two stocks.

Get MiniMed Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for MMED and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MMED vs. The Competition

MetricMiniMed GroupHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4.59B$5.86B$7.49B$11.54B
Dividend YieldN/A1.68%2.47%4.65%
P/E Ratio-24.0138.5132.9029.69
Price / Sales1.424.747.935.25
Price / CashN/A23.3720.8521.62
Price / Book1.274.154.403.67
Net Income-$333M$143.14M$3.51B$394.15M
7 Day Performance-8.81%-4.85%-5.70%-5.80%
1 Month Performance-8.35%-5.19%-6.54%-8.19%
1 Year PerformanceN/A-0.88%-2.02%-7.86%

MiniMed Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MMED
MiniMed Group
3.1743 of 5 stars
$16.18
-4.8%
$24.13
+49.1%
N/A$4.56B$3.22BN/A2,800
ZBH
Zimmer Biomet
3.7197 of 5 stars
$103.18
-1.3%
$112.74
+9.3%
+16.1%$19.79B$8.57B26.1217,000
GKOS
Glaukos
2.8098 of 5 stars
$245.60
-0.2%
$216.71
-11.8%
+153.8%$14.56B$507.44MN/A1,094
BAX
Baxter International
1.7185 of 5 stars
$25.77
+0.1%
$23.27
-9.7%
+43.9%$13.32B$11.24BN/A37,500
SNN
Smith & Nephew SNATS
1.9127 of 5 stars
$31.24
+0.8%
$31.91
+2.2%
-6.8%$12.98B$6.16BN/A16,988

Related Companies and Tools


This page (NASDAQ:MMED) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners